Successfully Met Primary and Secondary Endpoints, with Mean Placebo-Adjusted Reduction in Systolic Blood Pressure of 9.7 mmHg in Uncontrolled and Resistant Hypertensive Subjects at 50 mg Once Daily (p=0.01 vs. placebo)
News | Hypertension
Mineralys Therapeutics Announces Positive Topline Phase 2 Data for MLS-101 in the Target-HTN Trial Evaluating the Treatment of Uncontrolled and Resistant Hypertension

November 21, 2022 โ€” Mineralys Therapeutics, Inc., a private, clinical-stage biopharmaceutical company committed to ...

Home November 21, 2022
Home
Cardiovascular disease remains the leading cause of death in the United States (US) and worldwide, according to the American Heart Association.
News | Heart Failure
Defining preventive cardiology: A clinical practice statement from the American Society for Preventive Cardiology

November 21, 2022 โ€” Cardiovascular disease remains the leading cause of death in the United States (US) and worldwide ...

Home November 21, 2022
Home
Justin Balko, PharmD, PhD, Ingram Associate Professor of Cancer Research, and a co-corresponding author of the study. Credit: Vanderbilt University Medical Center
News | Heart Failure
Cardiac antigen identified as mechanism for heart complication with immunotherapy-related myocarditis

November 22, 2022 โ€” Myocarditis is a complication that can occur in cancer patients treated with immune checkpoint ...

Home November 21, 2022
Home
Screen shots of Viz PE with RV/LV ratio data (left), along with the companyโ€™s ECG Viewer (right). Both are part of the comprehensive Viz Cardio Suite designed to speed and improve patient access to innovative cardiovascular treatments. Source: Viz.ai.
News | Pulmonary Embolism
Viz.ai Launches AI-Powered Viz Cardio Suite

November 17, 2022 โ€” Viz.ai, a leader in AI-powered disease detection and intelligent care coordination, announced the ...

Home November 17, 2022
Home
Figure 1. Flow chart of machine learning workflow. A machine learning (ML) model for the prediction of vessel-specific ischemia was built, trained, and tuned in the NXT trial (Analysis of Coronary Blood Flow using CT Angiography: Next Steps). The modelโ€™s predictive performance was evaluated in the PACIFIC trial (Prospective Comparison of Cardiac Positron Emission Tomography [PET]/Computed Tomography [CT]โ€š Single Photon Emission Computed Tomography [SPECT]/CT Perfusion Imaging and CT Coronary Angiography wit
News | Computed Tomography (CT)
AI Tool Predicts Reduced Blood Flow to the Heart

November 17, 2022 โ€” Cedars-Sinai investigators and colleagues have developed an artificial intelligence (AI) tool that ...

Home November 17, 2022
Home
Enhanced offering gives hospitals flexibility to automate scan sequences from leading vendors into one scan protocol
News | Magnetic Resonance Imaging (MRI)
HeartVista, Siemens Healthineers Sign Commercial Agreement to Bring AI-Driven Image Acquisition to Hospital MRI Scanners

November 17, 2022 โ€” HeartVista, a pioneer in AI-assisted MRI solutions, and Siemens Healthineers, a global leader in ...

Home November 17, 2022
Home
Adds natural language processing to Viz.aiโ€™s AI-powered platform to detect suspected disease earlier and monitor patients
News | Artificial Intelligence
Viz.ai Partners with Illuminate to Improve Quality of Care for Aortic Aneurysm Patients

November 16, 2022 โ€” Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today ...

Home November 16, 2022
Home
Osso VR, now the largest and fastest-growing virtual reality (VR) company in healthcare, and the American College of Cardiology (ACC), a global nonprofit dedicated to transforming cardiovascular care, today announced a new collaboration to develop an immersive, VR-enabled training program for cardiovascular professionals.
News | Virtual and Augmented Reality
Osso VR and American College of Cardiology to Develop Immersive Training for Cardiovascular Professionals

November 16, 2022 โ€” Osso VR, now the largest and fastest-growing virtual reality (VR) company in healthcare, and the ...

Home November 16, 2022
Home
An AI algorithm applied to Apple Watch ECG recordings successfully identified a weak heart pump in patients
News | Artificial Intelligence
AI Transforms Smartwatch ECG Signals Into a Diagnostic Tool for Heart Failure

November 16, 2022 โ€” A study published in Nature Medicine reports the ability of a smartwatch ECG to accurately detect ...

Home November 16, 2022
Home
Certain adults with this artery-blocking condition may see more benefits with an open bypass compared to less-invasive procedures to improve circulation.
News | Peripheral Artery Disease (PAD)
Bypass Surgery Favorable for Initial Treatment of Chronic Limb-Threatening Ischemia

November 15, 2022 Performing open bypass surgery to restore circulation for people with a severe form of peripheral ...

Home November 15, 2022
Home
Edwin A. Takahashi, M.D., assistant professor of radiology in the division of interventional radiology at the Mayo Clinic College of Medicine in Rochester, Minnesota. Copyright Mayo Clinic College of Medicine
News | AHA
Telehealth is a Valuable Option in Cardiovascular Care, Though Challenges Remain

November 15, 2022 โ€” Telehealth is a proven and valuable option for people with cardiovascular disease, however, there ...

Home November 15, 2022
Home
UMSOM researchers display first genetically modified pig heart transplanted into living patient. Image courtesy of University of Maryland School of Medicine
News | Heart Failure
Unexpected Electrical Changes Seen in First Successful Transplant of Genetically-Modified Pig Heart

November 15, 2022 โ€” Ten months after transplanting the first genetically-modified pig heart into a human patient ...

Home November 15, 2022
Home
When it comes to heart failure (HF), sex differences are known to impact everything from risk factors to clinical presentation to response to treatment, making sex a key factor to consider in studies of emerging pharmacotherapies.
News | Heart Failure
Study Shows Heart Failure Treatment With Dapagliflozin Consistently Benefited Both Men and Women

November 14, 2022 โ€” When it comes to heart failure (HF), sex differencesare known to impact everything from risk factors ...

Home November 14, 2022
Home
Less complex heart patients may benefit, but not without risk
News | Pediatric Cardiology
Largest Randomized Trial Evaluates Steroids for Infant Heart Surgery

November 14, 2022 โ€” For more than four decades, doctors have been split on whether giving steroids during a pediatric ...

Home November 14, 2022
Home
Reduction in the risk of death or major bleeding after primary PCI in patients with STEMI treated with heparin monotherapy (blue curve) or bivalirudin with a post-procedure infusion (red curve). The hazard ratio of 0.69 signifies a 31% reduction in risk. The ARR (absolute risk reduction) was 1.3%. The NNT (number of patients needed to treat to prevent one death or large bleed) was 76. Image courtesy of Mount Sinai Health System
News | Antiplatelet and Anticoagulation Therapies
Bivalirudin Found to be Safer and More Effective Than Heparin for Treating Heart Attack Patients Undergoing Percutaneous Coronary Intervention

November 14, 2022 โ€” Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with the ...

Home November 14, 2022
Home
ยฉ Copyright Wainscot Media. All Rights Reserved.
Subscribe Now